Expand Image

≥99% PurityUS SynthesizedOut of Stock

CJC-1295 + Ipamorelin (No DAC) — Dual GHRH-R / GHSR-1a Research Stack | Mod GRF(1-29) + Ipamorelin Pentapeptide

Research-Grade Compound

CJC-1295 + Ipamorelin (No DAC) is a two-peptide research formulation combining CJC-1295 without DAC — a 29-amino-acid GHRH analog also known as Modified GRF(1-29) or Mod GRF 1-29 (C152H252N44O42, 3,367.9 Da, CAS 863288-34-0) — with ipamorelin, a selective GHSR-1a agonist pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, C38H49N9O5, 711.85 Da, CAS 170851-70-4). The standard vial supplies 5 mg of each component.

Select Size

$60.00$75.00USD / Unit

HPLC Verified

Same Day Shipping

Tesamorelin research guide — GHRH analog comparison →

In-depth research overview, mechanism of action, and study applications.

No variant-specific CoA for 10mg — showing product CoA

Certificate Details

Purity≥99%

Methodology

HPLCLC-MS/MS

SequenceModified GRF (1-29) — 29-amino-acid GHRH analog without Drug Affinity Complex

Verify Results with Testing Laboratory

Download PDF Open in New Tab Verify with Lab

This Certificate of Analysis was issued by an independent third-party laboratory. Peptide.Express does not conduct in-house testing. Results are provided as-is from the testing facility and confirm batch identity, purity, and analytical methodology. For questions about specific CoA results, contact [email protected].

≥99% by HPLCLC-MS/MS VerifiedCoA Every BatchIn-Vitro Research Use Only

What is CJC-1295 + Ipamorelin (No DAC)?

The "No DAC" designation is the part most often misread. CJC-1295 With DAC carries a Drug Affinity Complex, a maleimido-propionic acid group that binds covalently to circulating serum albumin and stretches the half-life out to days. Strip that moiety off and you get the No DAC form, whose half-life is measured in tens of minutes. Same GHRH-R target, radically different exposure profile: the DAC version produces a sustained elevation often described in the literature as a GH "bleed", while the No DAC version leaves the endogenous pulse architecture intact. Researchers who need physiological pulsatility use No DAC. Those who need sustained receptor occupancy use DAC. They are not interchangeable and the naming does very little to signal that.

Pairing the two compounds is a pathway argument rather than a dosing one. CJC-1295 No DAC acts at GHRH-R through Gs and cAMP; ipamorelin acts at GHSR-1a through Gq and calcium. Neither receptor is downstream of the other, and both terminate on the same somatotroph. Each component in the Peptide.Express blend is independently synthesized and HPLC-verified at ≥99% purity before compounding, with LC-MS/MS mass confirmation per component.

How Does CJC-1295 + Ipamorelin (No DAC) Work? Mechanism of Action

Two receptors, two G-proteins, two second-messenger systems, one shared endpoint. That is the whole design rationale for this stack, and it is a stronger argument than most peptide combinations can make — the pathways are separable in principle and can be measured independently.

CJC-1295 (No DAC) — GHRH-R and the cAMP-PKA Cascade

CJC-1295 No DAC activates GHRH-R on anterior pituitary somatotrophs. The receptor is a class B GPCR coupled to Gs; activation raises intracellular cAMP, protein kinase A phosphorylates CREB to drive GH1 transcription, and voltage-gated calcium influx triggers exocytosis of stored GH granules.

Structurally the molecule is sermorelin's 29-residue backbone with four amino acid substitutions — at positions 2, 8, 15 and 27 — carried over from the Modified GRF(1-29) design. The position 2 substitution is the load-bearing one: it removes the dipeptidyl peptidase IV cleavage site that destroys native GHRH within minutes. The other three improve receptor binding affinity and resistance to trypsin-like cleavage. The net gain is modest in absolute terms, roughly 30 minutes of plasma half-life against sermorelin's 10 to 20, but at 3,367.9 Da versus sermorelin's 3,357.9 Da the entire structural change amounts to about 10 daltons.

Worth stating plainly: there is no published human clinical trial dataset for the No DAC form. The clinical work on CJC-1295 was done on the DAC-bearing version. Anything asserted about No DAC pharmacokinetics in humans is extrapolated from the DAC literature and from the general Mod GRF 1-29 pharmacology, not measured.

Ipamorelin — GHSR-1a and Calcium-Mediated Release

Ipamorelin binds GHSR-1a, the ghrelin receptor, which couples to Gq rather than Gs. Phospholipase C cleaves PIP2 into IP3 and diacylglycerol; IP3 releases calcium from intracellular stores, DAG activates protein kinase C, and the calcium rise drives GH granule exocytosis. The cAMP system is not involved.

Ipamorelin also reduces somatostatin tone at the pituitary. Somatostatin is the physiological brake on somatotroph firing, so lowering it removes an inhibition at the same time the receptor stimulus is being applied.

Its selectivity is the reason it is the GHRP chosen for this pairing rather than GHRP-2 or GHRP-6. Those compounds also raise ACTH, cortisol and prolactin, which would confound any experiment where the hypothalamic-pituitary-adrenal axis matters. Ipamorelin's preclinical characterisation reports minimal effect on those markers across the doses tested.

Why the Two Are Combined — and What Has Not Been Tested

GHRH-R agonism increases the amount of GH available and the transcriptional drive behind it. GHSR-1a agonism increases the release stimulus and simultaneously lifts somatostatin inhibition. Applied together, these act on different limbs of the same regulatory system, and the co-administration literature on GHRH analogs plus GHRPs consistently reports a combined GH response larger than the sum of the individual responses. The mechanism for that is well understood in outline: the two signals are not competing for the same receptor pool, and one of them is removing a brake the other is pushing against.

The evidence gap is specific and worth naming. The synergy finding comes from the general GHRH-plus-GHRP literature, not from published studies of this particular 5 mg / 5 mg pre-blended combination. No combination pharmacokinetic data exists for CJC-1295 No DAC with ipamorelin. The half-lives also differ by roughly a factor of four — around 30 minutes for the GHRH component against approximately 2 hours for ipamorelin — which means the two signals are not coincident in time after a single administration. Any protocol using the blend is inferring from single-compound work, and study designs should say so rather than treating the pairing as a characterised entity.

Research Applications of CJC-1295 + Ipamorelin (No DAC)

Dual-Pathway GH Secretagogue Research

Pathway separation designs: running CJC-1295 No DAC alone, ipamorelin alone and the combination is the only way to attribute a GH response to cAMP signaling, calcium signaling or their interaction.
Somatotroph co-stimulation assays: simultaneous Gs and Gq activation on the same cell produces a second-messenger interaction that neither compound generates alone.
Somatostatin tone measurement: because ipamorelin lowers somatostatin while CJC-1295 pushes against it, the combination is used to probe where in the axis the inhibitory brake sits.

Pulsatility and Exposure-Profile Models

Pulsatile versus sustained GH: the No DAC form preserves endogenous pulse architecture, making it the comparator arm against DAC-bearing CJC-1295 in exposure-profile studies.
Half-life mismatch modeling: an approximately 30-minute GHRH component paired with a roughly 2-hour GHRP component gives non-coincident signals, which is itself a study variable rather than a flaw.
IGF-1 downstream tracking: hepatic IGF-1 output integrates GH exposure over time and is the standard secondary endpoint for combination protocols.

Comparative Analog Pharmacology

CJC-1295 No DAC versus sermorelin: a 10 Da structural difference across four substituted residues, which makes the pair a precise tool for measuring what protease resistance alone contributes.
CJC-1295 No DAC versus tesamorelin: two stabilisation strategies — residue substitution against N-terminal capping — applied to the same receptor.
GHRP class comparison: substituting GHRP-2 or GHRP-6 for ipamorelin in the same stack tests how much the cortisol and prolactin off-target profile changes the readout.

CJC-1295 With DAC vs CJC-1295 No DAC

Feature	CJC-1295 With DAC	CJC-1295 No DAC (this product)
Also known as	CJC-1295 DAC, CJC-1295 (long-acting)	Modified GRF(1-29), Mod GRF 1-29
Structural difference	Carries a Drug Affinity Complex — an albumin-binding moiety	No DAC moiety; the four core substitutions only
Molecular weight	Higher, reflecting the added DAC group	3,367.9 Da
CAS number	Distinct from the No DAC form	863288-34-0
Amino acid backbone	GRF(1-29) with four substitutions	GRF(1-29) with four substitutions
Receptor target	GHRH-R	GHRH-R
Second messenger	cAMP-PKA	cAMP-PKA
Approximate half-life	Days — albumin binding extends circulation time	Approximately 30 minutes
GH release profile	Sustained elevation, described as a GH "bleed"	Pulsatile, endogenous rhythm preserved
Somatostatin counter-regulation	Partially overridden by continuous receptor occupancy	Intact
Typical research use	Sustained receptor occupancy studies	Physiological pulsatility studies
Human clinical data	Published for the DAC-bearing form	Not published for the No DAC form
FDA status	Not approved	Not approved
WADA status	Prohibited at all times	Prohibited at all times

The two forms share a name, a backbone and a receptor, and almost nothing else about their behaviour in circulation. Pulsatility is the deciding variable — if the research question depends on GH arriving in pulses, DAC-bearing CJC-1295 answers a different question. Peptide.Express supplies the No DAC form specifically, and the molecular weight on the batch CoA is the fastest way to confirm which one is in the vial.

CJC-1295 + Ipamorelin (No DAC) Technical Specifications

Technical specifications for CJC-1295 + Ipamorelin (No DAC), including molecular data, purity standard, testing methods and storage requirements.
Compound Name	CJC-1295 (No DAC) + Ipamorelin research blend
Components	CJC-1295 No DAC (Mod GRF 1-29) and ipamorelin
Common Synonyms	CJC-1295 no DAC ipamorelin, Mod GRF 1-29 + ipamorelin, CJC/Ipa stack
Component 1 — Identity	CJC-1295 No DAC, Modified GRF(1-29), 29-amino-acid GHRH analog
Component 1 — Formula	C152H252N44O42
Component 1 — Molecular Weight	3,367.9 Da
Component 1 — CAS Number	863288-34-0
Component 1 — Receptor	GHRH-R, Gs-coupled, cAMP-PKA cascade
Component 1 — Approximate Half-Life	Approximately 30 minutes
Component 2 — Identity	Ipamorelin, Aib-His-D-2-Nal-D-Phe-Lys-NH2, pentapeptide
Component 2 — Formula	C38H49N9O5
Component 2 — Molecular Weight	711.85 Da
Component 2 — CAS Number	170851-70-4
Component 2 — Receptor	GHSR-1a, Gq-coupled, phospholipase C and calcium
Component 2 — Approximate Half-Life	~2 hours (reported)
Standard Vial Composition	5 mg CJC-1295 No DAC + 5 mg ipamorelin (10 mg total blend mass)
Purity	≥99% per component by HPLC
Purity Confirmation	LC-MS/MS molecular weight verification per component
Blend Verification	Compositional ratio verification post-blend
Endotoxin Testing	LAL (Limulus Amebocyte Lysate) method
Physical Form	Lyophilized powder blend
Appearance	White to off-white powder
Reconstitution	Bacteriostatic water, 2–3 mL for a standard 10 mg vial
Storage (lyophilized)	-20°C, desiccated, protected from light
Storage (reconstituted)	2–8°C, use within 14–28 days
Shelf Life	24 months from manufacture (lyophilized)
Testing Methods	HPLC, LC-MS/MS, LAL Endotoxin
Documentation	Certificate of Analysis (CoA) per batch, per component
FDA Status	Neither component is approved for any human indication
WADA Status	Both components prohibited at all times
Intended Use	In-vitro laboratory research only

How to Reconstitute CJC-1295 + Ipamorelin (No DAC) for Research

The arithmetic on a blend vial trips people up more often than the technique does. A 10 mg vial here is 5 mg of each component, so 2 mL of diluent gives 5 mg/mL of total blend mass but only 2.5 mg/mL of either individual peptide. Write down which figure you are working from before you draw anything, because the two numbers differ by a factor of two and the vial label will not resolve the ambiguity for you.

Bring the vial to room temperature before opening.
Draw the calculated volume of bacteriostatic water. For the standard 5 mg + 5 mg vial, 2 mL yields 5 mg/mL total blend mass — equivalent to 2.5 mg/mL of CJC-1295 No DAC and 2.5 mg/mL of ipamorelin. Using 2.5 mL yields 4 mg/mL total, or 2 mg/mL per component.
Swab the septum with alcohol and allow 30 seconds to dry.
Inject the diluent slowly against the inner vial wall, not onto the lyophilized cake.
Swirl gently for 60–90 seconds. The pentapeptide dissolves almost immediately; the 29-residue GHRH analog takes longer, so let the slower component set the timing. Do not shake.
Confirm the solution is clear and colorless with no particulate. Discard if cloudy or if a precipitate forms.
Label with the reconstitution date, the total blend concentration and the per-component concentration. Recording both prevents the most common downstream calculation error.
Store at 2–8°C and use within 14–28 days. Avoid repeated freeze-thaw cycles.

Diluent: bacteriostatic water for peptide reconstitution. Full protocol: step-by-step peptide reconstitution guide. Concentration maths: peptide reconstitution calculator.

Frequently Asked Questions — CJC-1295 + Ipamorelin (No DAC)

What is CJC-1295 No DAC?

CJC-1295 without DAC is a 29-amino-acid GHRH analog, also called Modified GRF(1-29) or Mod GRF 1-29. Molecular formula C152H252N44O42, molecular weight 3,367.9 Da, CAS 863288-34-0. It is the GRF(1-29) backbone carrying four amino acid substitutions that slow enzymatic cleavage and improve GHRH-R binding, with no albumin-binding moiety attached.

What is in this product?

Two peptides in one lyophilized vial: 5 mg of CJC-1295 No DAC (3,367.9 Da) and 5 mg of ipamorelin (711.85 Da). Each is independently synthesized and verified at ≥99% purity by HPLC with LC-MS/MS mass confirmation before the blend is compounded.

What is the difference between CJC-1295 with DAC and without DAC?

The DAC — Drug Affinity Complex — is an albumin-binding group. With it attached, the peptide binds circulating serum albumin and stays in the system for days, producing a sustained GH elevation. Without it, the half-life drops to roughly 30 minutes and the endogenous pulse architecture is preserved. Same receptor, same backbone, completely different exposure profile. Studies that depend on physiological pulsatility use the No DAC form; studies that need sustained receptor occupancy use the DAC form.

What is Mod GRF 1-29?

It is the same molecule as CJC-1295 No DAC. The name comes from what the compound actually is — GRF(1-29), the sermorelin backbone, modified at four positions. Suppliers use the two names interchangeably, which is a reasonable source of confusion given that "CJC-1295" on its own usually means the DAC-bearing version in the clinical literature.

Is CJC-1295 the same as sermorelin?

No, though they are closer than the different names suggest. Both are 29-residue GRF(1-29) peptides. CJC-1295 No DAC adds four amino acid substitutions at positions 2, 8, 15 and 27, which slow dipeptidyl peptidase IV cleavage and raise binding affinity. The mass difference is about 10 daltons — 3,367.9 Da against sermorelin's 3,357.9 Da — and the half-life difference is roughly 30 minutes against 10 to 20.

Why is CJC-1295 paired with ipamorelin in research?

Because they engage different receptors through different second messengers. CJC-1295 No DAC binds GHRH-R, which couples to Gs and raises cAMP. Ipamorelin binds GHSR-1a, which couples to Gq and raises intracellular calcium. Neither pathway is downstream of the other, and both converge on GH granule exocytosis in the same somatotroph — so the combination probes an interaction that neither compound can produce alone.

How does CJC-1295 + ipamorelin produce a larger GH response than either alone?

Two independent mechanisms operating in the same direction. The GHRH-R arm drives GH1 transcription and increases the releasable pool; the GHSR-1a arm supplies a calcium-mediated release stimulus and simultaneously reduces somatostatin tone, which is the physiological brake on somatotroph firing. Pushing the accelerator while releasing the brake is a fair description of the pharmacology. The finding comes from the general GHRH-plus-GHRP co-administration literature, not from published studies of this specific pre-blended product.

What is the half-life of CJC-1295 No DAC?

Approximately 30 minutes. That figure sits between native GHRH, which is cleaved within minutes, and tesamorelin, whose N-terminal cap blocks the cleavage site outright. Note the mismatch against the other component: ipamorelin persists for roughly 2 hours, so after a single administration the GHSR-1a signal outlasts the GHRH-R signal by a factor of about four. Whether the synergy depends on the two signals being coincident has not been formally tested for this pairing.

Is there published clinical data on CJC-1295 No DAC?

No. The human clinical work on CJC-1295 was done with the DAC-bearing form. Statements about No DAC pharmacokinetics in humans are extrapolated from that literature and from the broader Mod GRF 1-29 pharmacology rather than measured directly. Researchers should treat the No DAC half-life figures as approximate.

How do I reconstitute a 5 mg + 5 mg CJC-1295 + ipamorelin vial?

Add 2 mL of bacteriostatic water for 5 mg/mL of total blend mass, which works out to 2.5 mg/mL of each individual peptide. Inject the diluent down the inner vial wall rather than onto the powder, swirl for 60–90 seconds without shaking, then label the vial with both the total and per-component concentrations — the two figures differ by a factor of two in a 1:1 blend, and the batch Certificate of Analysis is the authoritative source for the compositional ratio. Store at 2–8°C and use within 14–28 days.

What purity standard does Peptide.Express use for this blend?

Each component is verified at ≥99% purity by reverse-phase HPLC before compounding, with LC-MS/MS confirming 3,367.9 Da for the CJC-1295 No DAC component and 711.85 Da for ipamorelin. The finished blend then receives compositional ratio verification. Checking the CJC mass on the CoA is the practical way to confirm you have the No DAC form rather than a DAC-bearing product.

What testing does the blend undergo before shipping?

Reverse-phase HPLC for purity by area-under-curve on each component, LC-MS/MS for molecular weight identity per component, LAL endotoxin testing, compositional ratio verification on the finished blend, and visual QC. All testing is performed by an independent third-party laboratory.

How should the blend be stored before and after reconstitution?

Lyophilized: -20°C, desiccated, protected from light, stable for 24 months from manufacture. Reconstituted: 2–8°C, used within 14–28 days. Do not freeze the reconstituted solution — the two components have different aggregation behaviour under thermal cycling, so freeze-thaw damage does not affect the blend evenly.

Where is the Certificate of Analysis for this blend?

On this page and in the Peptide.Express lab results library. The CoA is batch-specific and lists per-component HPLC purity, per-component LC-MS/MS mass confirmation, the compositional ratio, endotoxin result, testing laboratory and test date.

Research References

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." Journal of Clinical Endocrinology & Metabolism, 2006. Read the CJC-1295 (DAC) human dosing study on PubMed
Raun K, et al. "Ipamorelin, the First Selective Growth Hormone Secretagogue." European Journal of Endocrinology, 1998. Read the Raun ipamorelin selectivity study on PubMed
Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. "Growth Hormone (GH)-Releasing Peptide Stimulates GH Release in Normal Men and Acts Synergistically with GH-Releasing Hormone." Journal of Clinical Endocrinology & Metabolism, 1990. Read the GHRP and GHRH co-administration synergy study on PubMed
For a GHRH analog with published human trial data, the tesamorelin record is the closest available reference point. Falutz J, et al. Journal of Clinical Endocrinology and Metabolism, 2008. Read the tesamorelin long-term safety study on PubMed

All products are sold for in-vitro laboratory research use only. Not intended for human consumption, clinical use, or veterinary use. Peptide.Express makes no medical claims. Consult the published literature for research application guidance.